Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 3 - What They Never Told You

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Top News

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

What was the longest-running Covid infection and how were they cured?

A British man tested positive for Covid for more than two years and survived - but many more have Long Covid

Evening Standard

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

A Colorado teen’s long COVID isn’t just persisting — after 2 years, it’s getting worse

DENVER -- Reminders of life outside Lilly Downs’ Denver hospital room dotted the walls.

The Denver Post

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Benzinga

How Donald Trump’s fight with Covid unfolded two years before Biden diagnosis

Low blood oxygen levels and lung issues led officials to believe Trump might have to be put on ventilator in 2020

The Independent UK

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Benzinga

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The U.S.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV. The company reported a net income of $974 million, down 13%, as its COVID-19…

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary technology to harness the immune system's power to combat cancer. The offer price represents a whopping premium of over 300% on…

Benzinga

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the comp

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy

The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.